Genmab — Juni 2022
-
NEW TRIAL: A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy https://www.clinicaltrials.gov/ct2/show/NCT05435339
-
Kig med den 29. juni så kan det være vi kan spotte target https://investors.biontech.de/news-releases/news-release-details/biontech-host-first-edition-innovation-series-diversified
-
Tirsdagens aktier: SAS i hopla - defensive aktier tyngede rødt C25
https://www.proinvestor.com/investornyt/843585/tirsdagens-aktier-sas-i-hopla-defensive-aktier-tyngede-rodt-c25 -
USA/middag: Tech presser aktierne ned - energi igen i front
https://www.proinvestor.com/investornyt/843619/usa-middag-tech-presser-aktierne-ned-energi-igen-i-front -
USA/lukning: Solide plusser vendt til tunge minusser
https://www.proinvestor.com/investornyt/843702/usa-lukning-solide-plusser-vendt-til-tunge-minusser -
God morgen.
-
https://jeccr.biomedcentral.com/articles/10.1186/s13046-022-02421-2 Expanding anti-CD38 immunotherapy for lymphoid malignancies
-
Aktier/middag: Plus til Mærsk i nervøs og tynd handel
https://www.proinvestor.com/investornyt/843868/aktier-middag-plus-til-maersk-i-nervos-og-tynd-handel -
-
can't see anything about GEN1053 in the BionTech presentation, but they will discuss GEN1046 (BNT311) and
GEN1042 (BNT312) https://investors.biontech.de/static-files/edee73bd-1620-4f51-a419-7ce7782ffa0f
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind